REPLIGEN CORP (RGEN) Form 10-Q — Oct 30, 2026
Repligen reported Q3 2026 revenue of $209.3 million, up 10.9% year-over-year, with growth across all product franchises including 55% growth in chromatography. However, the company swung to a GAAP net loss of $38.4 million (-$0.68 per share) versus $14.9 million net income a year ago, driven primarily by a $41.2 million intangible asset impairment charge tied to an intellectual property license agreement. The company disclosed that its disclosure controls remain not effective due to previously reported material weaknesses in IT general controls and business process controls around inventory valuation and financial close, which have not yet been remediated as of September 30, 2026.
Key figures
- Revenue
- 209314000
- Total Debt
- 555596000
- Revenue Yoy
- 10.9%
- Total Assets
- 2926408000
- Cash Position
- 726960000
- Shares Outstanding
- 63923738
- Q3 gross margin
- 53.0%
- Total liquidity
- $863.0 million
- Nine month revenue
- 607697000
- Nine month net loss
- $25.1 million
- Biolife cash portion
- $564 million
- New convertible notes
- $1.0 billion of 0.25% Convertible Senior Notes due 2031
- Nine month revenue yoy
- 12.5%
- Polymem divestiture loss
- $13.7 million
- Biolife acquisition value
- $1.9 billion
- Intangible impairment charge
- $41.2 million
- Operating cash flow nine months
- $104.2 million
- Share repurchase from note proceeds
- $120.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.